HARVARD BIOSCIENCE, INC.

Analyst Reco. Harvard Bioscience, Inc.

Equities

HBIO

US4169061052

Market Closed - Nasdaq Other stock markets 21:00:00 25/06/2024 BST			5-day change	1st Jan Change
2.91 ^USD	+2.11%		-1.02%	-45.61%

05-07	Transcript : Harvard Bioscience, Inc., Q1 2024 Earnings Call, May 07, 2024
05-07	Earnings Flash (HBIO) HARVARD BIOSCIENCE Posts Q1 Revenue $24.5M	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Benchmark Adjusts Price Target on Harvard Bioscience to $7 From $4, Maintains Buy Rating	26/04/23	MT
Keybanc Adjusts Price Target on Harvard Bioscience to $7 From $5, Maintains Overweight Rating	26/04/23	MT
KeyBanc Capital Markets Trims Price Target on Harvard Bioscience to $5 From $7, Maintains Overweight Rating	09/11/22	MT
KeyBanc Capital Markets Trims Price Target on Harvard Bioscience to $7 From $10, Keeps Overweight Rating	05/08/22	MT
HARVARD BIOSCIENCE : Northland Capital Starts Harvard Bioscience at Outperform With $6 Price Target	09/12/20	MT
HARVARD BIOSCIENCE : KeyBanc Initiates Harvard Bioscience at Overweight with $6 Price Target	10/11/20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Our Free Content Help you Secure and Increase the Performance of Your Investments

Securing my Investments

fermer